✦ LIBER ✦

Su1026 Statin Use Reduces Risk of Progression of Liver Fibrosis, Among Patients With Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial

✍ Scribed by Simon, Tracey G.; King, Lindsay Y.; Zheng, Hui; Chung, Raymond T.

Book ID: 123361326
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 374 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)63517-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evolution of hepatic steatosis in patien

Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial

✍ Anna S. Lok; James E. Everhart; Raymond T. Chung; Hae-Young Kim; Gregory T. Ever 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB 👁 2 views

Hepatic steatosis is a common histologic feature in patients with chronic hepatitis C (CHC) but there are no large longitudinal studies describing the progression of steatosis in CHC. We examined changes in steatosis on serial biopsies among CHC patients participating in the Hepatitis C Antiviral Lo

Dietary Cholesterol Intake Is Associated

Dietary Cholesterol Intake Is Associated With Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial

✍ Yu, Lei; Morishima, Chihiro; Ioannou, George N. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 272 KB

Prognostic value of Ishak fibrosis stage

Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ James E. Everhart; Elizabeth C. Wright; Zachary D. Goodman; Jules L. Dienstag; J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB 👁 2 views

Studies of the prognostic value of Ishak fibrosis stage are lacking. We used multi-year follow-up of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial to determine whether individual Ishak fibrosis stages predicted clinical outcomes in patients with chronic hepatitis C.

Interferon Inhibits Progression of Liver

Interferon Inhibits Progression of Liver Fibrosis and Reduces the Risk of Hepatocarcinogenesis in Patients with Chronic Hepatitis C: A Retrospective Multicenter Analysis of 652 Patients

✍ Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; 📂 Article 📅 2002 🏛 Springer US 🌐 English ⚖ 72 KB

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may

YKL-40 genetic polymorphisms and the ris

YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C

✍ Robert J. Fontana; Heather J. Litman; Jules L. Dienstag; Herbert L. Bonkovsky; G 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB